These results may explain the “cancer stealth” effects by tumor-secreting Gal-3 or consumption of the inhibitors due to unspecific binding to other Galectins, in which we proposed that a larger dose of specific Gal-3 inhibitor may resolve the clinical dilemma. The gene discussed is LGALS3; the disease is cancer.